SCHEMBL4351998

SCHEMBL4351998

Cc1ccc(Sc2ccccc2CNc2cccc(C(=O)O)c2O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
HPGD P15428 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
KDM4C Q9H3R0 3/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
MMP12 P39900 2/20 0.41
POLB P06746 2/20 0.41
GAA P10253 1/20 0.41
HSP90AA1 P07900 1/20 0.41
SLC16A3 O15427 1/20 0.41
MMP14 P50281 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4349521 0.92 SIRT1 (0.47) SMN1; SMN2LMNAL3MBTL1TDP1CYP2C9
SCHEMBL4342487 0.88 LMNA (0.48) SMN1; SMN2NPC1RAB9ALMNAL3MBTL1
SCHEMBL4354379 0.88 MMP2 (0.57) SMN1; SMN2NPC1RAB9ALMNAHPGD
SCHEMBL4342203 0.87 KDM4E (0.47) SMN1; SMN2NPC1RAB9ALMNAL3MBTL1
SCHEMBL4353814 0.84 KMT2A (0.49) SMN1; SMN2RAB9ALMNACYP2C9CYP2C19
SCHEMBL4347450 0.84 PTGES (0.47) NPC1RAB9ALMNAALDH1A1POLB
SCHEMBL4341565 0.83 PTPRG (0.46) SMN1; SMN2NPC1RAB9ALMNATDP1
SCHEMBL4346119 0.83 MEN1 (0.41) SMN1; SMN2LMNAL3MBTL1TDP1CYP2C9
SCHEMBL4342190 0.82 SLC6A2 (0.43) SMN1; SMN2LMNAL3MBTL1TDP1CYP2C9
SCHEMBL4345359 0.82 SLC6A4 (0.40) SMN1; SMN2LMNAL3MBTL1TDP1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 SMN1; SMN2 1791/4885NPC1 815/4885RAB9A 4228/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 SMN1; SMN2 3250/4885NPC1 1189/4885RAB9A 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.